Treatment Protocol for Seizure Disorder
For adults with new-onset seizure disorder, initiate antiseizure medication (ASM) after 2 unprovoked seizures, or after 1 unprovoked seizure if it occurred during sleep, with epileptiform EEG activity, or with structural brain lesion on MRI; for focal epilepsy, start oxcarbazepine or lamotrigine as first-line therapy, and for status epilepticus, use intravenous levetiracetam, fosphenytoin, or valproate as second-line agents after benzodiazepines. 1, 2
Acute Management of Active Seizures
Status Epilepticus Protocol
When a patient presents with ongoing seizures lasting >5 minutes or recurrent seizures without return to baseline:
First-line treatment: Benzodiazepines (lorazepam, diazepam, or midazolam) 3
Second-line treatment (if seizures persist after benzodiazepines): The ESETT trial demonstrated equivalent efficacy among three options 2:
- Levetiracetam: 47% seizure cessation at 60 minutes (median time 10.5 minutes)
- Fosphenytoin: 45% seizure cessation (median time 11.7 minutes)
- Valproate: 46% seizure cessation (median time 7.0 minutes)
All three medications showed no significant difference in effectiveness, so selection should be based on patient-specific factors rather than efficacy 2. The trial included 384 patients and was stopped early for futility in finding a superior agent.
Third-line treatment: For refractory status epilepticus (RSE), anesthetic agents are indicated when ongoing seizures pose greater risk than treatment itself 3. Options include phenobarbital, additional ASMs, or general anesthesia depending on seizure semiology.
Critical caveat: General anesthesia is NOT indicated for continuous partial epilepsy, and for complex partial status epilepticus, exhaust multiple ASM options before proceeding to anesthesia 3.
Long-Term Management After Diagnosis
When to Initiate Chronic ASM Therapy
Treatment should be strongly considered in these scenarios 1, 4:
- After 2 unprovoked seizures
- After 1 unprovoked seizure that occurred during sleep
- After 1 unprovoked seizure with epileptiform activity on EEG
- After 1 unprovoked seizure with structural brain lesion on MRI
Do NOT treat acute symptomatic seizures with long-term ASMs unless they meet status epilepticus criteria 5. Treat the underlying cause instead.
First-Line ASM Selection by Epilepsy Type
For Focal Epilepsy:
Primary options 1:
- Oxcarbazepine (first choice based on cost-effectiveness and efficacy)
- Lamotrigine (co-first choice)
- Levetiracetam (acceptable if no psychiatric history)
The evidence shows 24 FDA-approved medications have similar efficacy for focal epilepsy, but oxcarbazepine and lamotrigine emerge as preferred first-line agents 1. Carbamazepine is most cost-effective but has more drug interactions and adverse effects 6.
Avoid in focal epilepsy: Enzyme-inducing ASMs (carbamazepine, phenytoin) in patients with cardiovascular disease, osteoporosis risk, or multiple concomitant medications due to accelerated drug metabolism and metabolic complications 1.
For Generalized Epilepsy:
Selection depends on specific epilepsy syndrome, patient sex, age, and psychiatric history 1. Nine medications have similar efficacy for generalized epilepsy, but the choice must account for:
- Valproate: Highly effective but teratogenic—avoid in women of childbearing potential 7
- Lamotrigine: Safer in pregnancy
- Levetiracetam: Avoid with psychiatric comorbidity
Medication Selection Algorithm
Step 1: Classify seizure type (focal vs. generalized) and epilepsy syndrome
Step 2: Assess patient factors:
- Age and sex (teratogenicity concerns in women of childbearing age)
- Psychiatric comorbidities (25-50% of epilepsy patients have mood, anxiety, or attention disorders) 1
- Cardiovascular disease (avoid enzyme-inducers)
- Bone health (avoid enzyme-inducers if osteoporosis risk)
- Concomitant medications (drug interaction potential)
Step 3: Select ASM based on above:
- Focal epilepsy without comorbidities: Oxcarbazepine or lamotrigine
- Focal epilepsy with psychiatric history: Lamotrigine (avoid levetiracetam)
- Focal epilepsy with cardiovascular disease: Levetiracetam or lamotrigine (avoid carbamazepine/phenytoin)
- Generalized epilepsy in women of childbearing age: Lamotrigine or levetiracetam (avoid valproate)
Monitoring and Adjustment
Expected outcome: Seizure freedom in 60-70% of patients 1
If seizures persist after 2 appropriate ASM trials: Patient is medically refractory and requires referral to certified epilepsy center for surgical evaluation, dietary therapy (ketogenic diet), or device therapy (vagus nerve stimulation, responsive neurostimulation) 8.
Critical Pitfalls to Avoid
Do NOT prescribe benzodiazepines or ASMs for functional (psychogenic) seizures without co-occurring epilepsy—these medications lack evidence of benefit and carry significant risks 9. If ASMs were started before functional seizures were diagnosed, taper them off.
Do NOT use prophylactic ASMs for all stroke patients or after single provoked seizures 10. Acute symptomatic seizures require treatment of the underlying cause, not chronic ASM therapy.
Do NOT delay specialist referral for drug-resistant epilepsy (failure of 2 appropriate ASMs). Early surgical evaluation significantly improves outcomes 7.
Do NOT overlook comorbidities: Screen all epilepsy patients for psychiatric disorders, cognitive impairment, and cardiovascular disease, as these affect both ASM selection and overall mortality risk 1, 7.